DrugPatentWatch Database Preview
Cppi Cv Company Profile
What is the competitive landscape for CPPI CV, and what generic alternatives to CPPI CV drugs are available?
CPPI CV has one approved drug.
There are three US patents protecting CPPI CV drugs.
There are sixty-eight patent family members on CPPI CV drugs in thirty-nine countries and twenty-one supplementary protection certificates in ten countries.
Summary for Cppi Cv
| International Patents: | 68 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Cppi Cv
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-003 | Jan 26, 2006 | RX | Yes | Yes | 6,573,293 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-001 | Jan 26, 2006 | RX | Yes | No | 7,125,905 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-003 | Jan 26, 2006 | RX | Yes | Yes | 7,125,905 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-004 | Mar 31, 2009 | RX | Yes | No | 7,125,905 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CPPI CV drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 12.5 mg, 25 mg, 37.5 mg and 50 mg | ➤ Subscribe | 2010-01-26 |
International Patents for Cppi Cv Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| New Zealand | 519697 | ➤ Try a Free Trial |
| Mexico | PA02006263 | ➤ Try a Free Trial |
| Netherlands | 300430 | ➤ Try a Free Trial |
| Portugal | 1255752 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Cppi Cv Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0003 | France | ➤ Try a Free Trial | PRODUCT NAME: TOCERAMIB ET OPTIONELLEMENT SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, ET EN PARTICULIER LE PHOSPHATE DE TOCERANIB; REGISTRATION NO/DATE IN FRANCE: EU/2/09/100/001 DU 20090923; REGISTRATION NO/DATE AT EEC: EU/2/09/100/001 DU 20090923 |
| 407 | Luxembourg | ➤ Try a Free Trial | 91407, EXPIRES: 20210719 |
| 2008002,C1255752 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: SUNITINIBUM; REGISTRATION NO/DATE: EU/1/06/347/001, EU/1/06/347/002, EU/1/06/347/003 20060719 |
| C/GB10/008 | United Kingdom | ➤ Try a Free Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/008 GRANTED TO SUGEN INC. AND PHARMACIA AND UPJOHN COMPANY LLC IN RESPECT OF THE PRODUCT TOCERANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE PHOSPHATE SALT.?, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6380 DATED 31 AUGUST 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 24 SEPTEMBER 2024 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
